Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial

Open access
Findling, Robert L., Landbloom, Ronald L., Mackle, Mary, Wu, Xiao, Snow-Adami, Linda, Chang, Kiki, Durgam, Suresh · 2016 · Pediatric Drugs

Abstract

BACKGROUND: Sublingually administered asenapine was approved in March 2015 by the United States Food and Drug Administration for patients aged 10-17 years with an acute manic or mixed episode associated with bipolar I disorder (BP-1). This is the first long-term safety and tolerability study of asenapine in this population. METHODS: Following the 3-week randomized, double-blind, placebo-controlled trial of patients aged 10-17 years with an acute manic or mixed episode associated with BP-1, patients could enroll in this flexible-dose (2.5-10 mg twice daily) open-label extension (OLE) study for an additional 50 weeks, conducted from August 2011 to September 2014 in the United States and Russia. Treatment-emergent adverse events (TEAEs) were assessed and predefined TEAEs of interest reported in addition to metabolic and anthropometric parameters. The Young Mania Rating Scale (YMRS) and Clinical Global Impressions scale in bipolar illness (CGI-BP) were used to assess effectiveness. RESULTS: A total of 321 patients (lead-in study treatment: placebo, n = 80; asenapine, n = 241) were included; 267 (83.2 %) reported one or more TEAE and 181 (56.4 %) discontinued early, 48 (15.0 %) due to TEAEs. Of the predefined TEAEs of interest, combined somnolence/sedation/hypersomnia occurred most frequently (42.4 %) followed by oral hypoesthesia/dysgeusia (7.5 %). In total, 109 (34.8 %) patients experienced clinically significant weight gain (≥7 % increase). No clinically meaningful changes were noted for laboratory parameters measured. Eighteen patients met the criteria for new-onset metabolic syndrome (MBS) post-baseline during the extension study, whereas 10 patients who met MBS criteria at baseline did not meet MBS criteria at endpoint. A total of 12 patients met MBS at baseline and endpoint. Mean change in YMRS total score from OLE baseline was -9.2 points at week 50, and change in CGI-BP severity overall score was similar among all treatment groups (those who initially received asenapine and those who initially received placebo). After 26 weeks of treatment in the OLE, 79.2 % of patients were classified as YMRS 50 % responders relative to acute trial baseline. CONCLUSIONS: Asenapine was generally well tolerated in pediatric patients with BP-1 during ≤50 weeks of open-label treatment; among predefined TEAEs of interest, the combination of somnolence/sedation/hypersomnia was the most common. Trial registration ClinicalTrials.gov: NCT01349907.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40272-016-0184-2

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient disposition. aDiscontinued and Completed consists of a mixture of patients who discontinued/completed the 26-week and 50-week versions of the protocol; bthe most common adverse events leading to treatment discontinuation were due to disease under study and occurred in 3 patients from the placebo/asenapine group and 10 patients from the asenapine/asenapine group (13 patients in total)
Fig. 1 Patient disposition. aDiscontinued and Completed consists of a mixture of patients who discontinued/completed the 26-week and 50-week versions of the protocol; bthe most common adverse events leading to treatment discontinuation were due to disease under study and occurred in 3 patients from the placebo/asenapine group and 10 patients from the asenapine/asenapine group (13 patients in total)CC BY-NC · PubMed Central
Fig. 2 Efficacy during the open-label extension (OC, full analysis set). a Least squares mean change from acute phase baseline in YMRS total score to end of treatment by visit; b Mean (SD) change in CGI-BP overall score from acute phase baseline to end of treatment by visit. The CGI-BP overall score ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Decreases from baseline within a treatment group were indicative of an improvement. The YMRS total score could range from 0 (all symptoms absent) to 60 (all symptoms extreme). Decreases from baseline within a treatment group are indicative of an improvement in symptoms. Full analysis set is all patients ≤17 years of age who received ≥1 dose of trial medication and had both baseline and ≥1 post-baseline in-treatment YMRS total scores in the acute and extension trial. CGI-BP Clinical Global Impression scale for use in bipolar illness, OC observed case, SD standard deviation, YMRS Young Mania Rating Scale
Fig. 2 Efficacy during the open-label extension (OC, full analysis set). a Least squares mean change from acute phase baseline in YMRS total score to end of treatment by visit; b Mean (SD) change in CGI-BP overall score from acute phase baseline to end of treatment by visit. The CGI-BP overall score ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Decreases from baseline within a treatment group were indicative of an improvement. The YMRS total score could range from 0 (all symptoms absent) to 60 (all symptoms extreme). Decreases from baseline within a treatment group are indicative of an improvement in symptoms. Full analysis set is all patients ≤17 years of age who received ≥1 dose of trial medication and had both baseline and ≥1 post-baseline in-treatment YMRS total scores in the acute and extension trial. CGI-BP Clinical Global Impression scale for use in bipolar illness, OC observed case, SD standard deviation, YMRS Young Mania Rating ScaleCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 53

Metadata

Authors
Findling, R. L., Landbloom, R. L., Mackle, M., Wu, X., Snow-Adami, L., Chang, K., & Durgam, S.
Affiliations
  • Kennedy Krieger Institute (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Allergan (United States) (US)
  • Lucile Packard Children's Hospital (US)
Corresponding author
Findling, Robert L.
Venue
Pediatric Drugs
Published
2016-07-26
Volume
18
Issue
5
Pages
367-378
ISSN
  • 1174-5878 (ISSN-L)
  • 1179-2019
OpenAlex
W2479858292
Cited by
53
References
26
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 26 · 2018: 6 · 2017: 6
FWCI
11.25
Type
journal article
Language
en
Open access
Locations
  • Pediatric Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Merck
  • Forest Laboratories
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
asenapine, bipolar I disorder, pediatric bipolar disorder, manic episodes, long-term safety, tolerability, treatment-emergent adverse events, sleepiness, weight gain, metabolic syndrome, open-label extension, Young Mania Rating Scale, antipsychotic efficacy
MeSH terms
Adolescent, Bipolar Disorder, Child, Dibenzocycloheptenes, Double-Blind Method, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Male, Psychiatric Status Rating Scales, Russia, Antipsychotic Agents, United States, United States Food and Drug Administration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. https://app.cochat.ai/papers/10.1007/s40272-016-0184-2
The paper
Findling, R. L., Landbloom, R. L., Mackle, M., Wu, X., Snow-Adami, L., Chang, K., & Durgam, S. (2016). Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Pediatric Drugs. https://doi.org/10.1007/s40272-016-0184-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.